501 - Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo

剂量范围研究 白癜风 医学 双盲 测距 随机对照试验 外科 皮肤病科 病理 地理 大地测量学 安慰剂 替代医学
作者
Thierry Passeron,Khaled Ezzedine,Iltefat Hamzavi,Nanja van Geel,Bethanee J. Schlosser,Xiaofei Hu,Xiaohong Huang,David Rosmarin,John E. Harris,Heidi S. Camp,Amit G. Pandya
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:190 (Supplement_2): ii65-ii66 被引量:2
标识
DOI:10.1093/bjd/ljad498.066
摘要

Abstract Introduction & Objectives Janus kinase (JAK) inhibition is a promising approach for the treatment of vitiligo. Here, we report the clinical efficacy and safety of upadacitinib (UPA), an oral JAK inhibitor, in a phase 2b multicenter, randomized, double-blind, placebo-controlled study of adults with extensive non-segmental vitiligo (NSV). Materials & Methods Eligible patients were aged 18–65 years with NSV, a Facial Vitiligo Area Scoring Index (F-VASI) of ≥0.5, and a Total Vitiligo Area Scoring Index (T-VASI) of ≥5 at baseline. This 52-week study (NCT04927975) comprised 2 periods. In period 1, patients were randomly assigned to once daily UPA 22 mg (UPA22), UPA 11 mg (UPA11), UPA 6 mg (UPA6), or placebo (PBO) for 24 weeks of treatment. In a 28-week blinded extension (period 2), patients receiving UPA during period 1 continued their respective regimens; patients who received PBO in period 1 were pre-assigned to either UPA11 or UPA22. Clinical efficacy endpoints evaluated through week 36 included percent change from baseline (%CFB) in F-VASI (week 24, primary endpoint), reductions from baseline in F-VASI of ≥50% (F-VASI 50) and ≥75% (F-VASI 75), %CFB in T-VASI, and reduction from baseline in T-VASI of ≥50% (T-VASI 50). Safety data as of January 13, 2023 (data cutoff date) are presented. Results Of the 185 patients enrolled in period 1, 165 (89.2%) continued to period 2. At baseline, 68% of patients had extensive vitiligo (T-VASI > 10), and 71% had active vitiligo. At week 24, the %CFB in F-VASI was greater with UPA11 (−35.6%) and UPA22 (−34.0%) vs PBO (−14.4%; nominal P = .005 and P = .013, respectively). A greater proportion of patients achieved F-VASI 50 and F-VASI 75 with UPA11 (38.3%, 19.1%) and UPA22 (39.5%, 14.0%) vs PBO (10.9%, 2.2%; nominal P < .05 for both doses and for both endpoints). Likewise, the %CFB in T-VASI was greater with UPA11 (−17.3%) and UPA22 (−20.7%) vs PBO (−6.4%; nominal P = .026 and P = .005, respectively). A higher percentage of patients achieved T-VASI 50 with UPA22 (11.6%) than with PBO (2.2%; nominal P = .027). UPA efficacy continued to improve through week 36, with %CFB in F-VASI for UPA6, UPA11, and UPA22 of −20.8%, −44.9% and −47.7%, respectively. At week 36, F-VASI 50 was achieved with UPA6, UPA11, and UPA22 by 34.2%, 54.3% and 61.5% of patients and F-VASI 75 by 15.8%, 40.0%, and 30.8%, respectively. At week 36, %CFB in T-VASI for UPA6, UPA11 and UPA22 were −24.3%, −32.0% and −37.6%, with 10.5%, 20.0% and 19.2% of patients, respectively, achieving T-VASI 50. Treatment-emergent adverse event (TEAE) rates were generally similar with UPA and PBO in period 1 (most common TEAEs: COVID-19, acne, fatigue, and headache) and were similar across treatment arms in period 2. One death adjudicated as undetermined/unknown cause and deemed by the investigator to have no reasonable possibility of being related to study drug occurred in the UPA22 group (period 1). One adjudicated event of nonfatal ischemic stroke occurred with UPA11 (period 2). There were no adjudicated events of venous thromboembolism, gastrointestinal perforation, or events of opportunistic infection, active tuberculosis, or malignancy. Conclusion Treatment with UPA for 24 weeks resulted in greater improvements vs PBO in the clinical outcomes of adults with extensive NSV. Observed clinical efficacy continued to improve through week 36 with UPA treatment. UPA was generally well tolerated, with no new safety signals ­identified.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
葛藟萦藤完成签到,获得积分10
刚刚
王书瑜发布了新的文献求助10
1秒前
1秒前
1秒前
量子星尘发布了新的文献求助10
2秒前
Jasper应助liqian采纳,获得10
2秒前
liangguangyuan完成签到 ,获得积分10
2秒前
人间枝头应助文件撤销了驳回
2秒前
3秒前
3秒前
4秒前
5秒前
Yuanchaoyi完成签到,获得积分20
5秒前
务实凡灵完成签到,获得积分10
6秒前
疯了半天完成签到,获得积分10
6秒前
王强完成签到,获得积分10
7秒前
7秒前
dong东包发布了新的文献求助10
8秒前
西瓜完成签到 ,获得积分10
8秒前
小张完成签到,获得积分10
9秒前
EVEN发布了新的文献求助30
10秒前
王冉冉发布了新的文献求助10
10秒前
10秒前
研无止境w发布了新的文献求助10
11秒前
13秒前
奶油泡fu完成签到 ,获得积分10
13秒前
dong东包完成签到,获得积分20
14秒前
14秒前
ED应助cccccc采纳,获得10
14秒前
shangziru发布了新的文献求助10
15秒前
漠之梦完成签到,获得积分20
16秒前
sc完成签到,获得积分10
16秒前
谦让的含海完成签到,获得积分10
16秒前
好运連連完成签到,获得积分10
17秒前
19秒前
liu完成签到,获得积分10
19秒前
飞翔的霸天哥应助Yuanchaoyi采纳,获得30
20秒前
香蕉觅云应助WJH采纳,获得10
21秒前
汉堡包应助研友_LOoomL采纳,获得10
21秒前
小二郎应助Felix采纳,获得10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048